Products Categories

CAR-T for Systemic Lupus Erythematosus (SLE)

Sickle Cell Disease & Thalassemia

Innovative Gene Therapy Offers New Hope for Sickle Cell and Thalassemia Patients

FUCASO: The Revolutionary Fully-Human BCMA CAR-T Therapy with Unmatched Efficacy and Safety

Harnessing NK Cells: Advancing Cancer Therapy Beyond Boundaries

TIL Therapy Unveiled: Exploring the Landscape of Cancer Immunotherapy

A Comprehensive Overview of Groundbreaking Leukemia Treatment

0102030405

A Comprehensive Overview of Groundbreaking Leukemia Treatment

CAR-T Therapy, short for Chimeric Antigen Receptor T-Cell Immunotherapy, is an advanced gene therapy method that involves genetically modifying a patient's own T cells to target and destroy cancer cells. Unlike traditional medications, CAR-T therapy is tailored to each patient and requires collecting T cells from the patient's blood before reinfusing them back into the body after genetic engineering.

Indications of CAR-T

● B-cell acute lymphoblastic leukemia

● Multiple myeloma

● Chronic lymphocytic leukemia

● Non-Hodgkin lymphoma

● Diffuse large B-cell lymphoma

● SLE（Systemic Lupus Erythematosus）

● Myasthenia gravis

● Other autoimmune diseases

Excellent CAR-T clinical performance

Indications for CD19+20CAR-T: Patients with B-cell non Hodgkin's lymphoma

One month CR rate	One month PR rate	One month OR rate	CRS≥3	CRES≥3
71.95%（59/82）	25.6（21/82）	97.55（80/82）	12.19%（10/82）	0

Indications for CD19+22CAR-T: Treatment of CD19 relapsed and refractory acute B-lymphocytic leukemia patients

One month CR rate	One month PR rate	One month OR rate	CRS≥3	CRES≥3
92.1%（35/38）	7.9%（3/38）	100%（38/38）	15.79%（6/38）	0

Indications for BCMACAR-T: Treatment of relapsed and refractory multiple myeloma

One month CR rate	One month PR rate	One month OR rate	CRS≥3	CRES≥3
72.41%（21/29）	27.59%（8/29）	100%（29/29）	6.9%（2/29）	0

Our Advantages

● Personalized Treatment: Each CAR-T therapy is customized to the patient, ensuring highly targeted and effective treatment outcomes.

● Diverse Targeting Options: With a wide range of target antigens, including CD7, CD19, CD20, CD22, and BCMA, our CAR-T products offer unparalleled versatility in treating various hematological malignancies and autoimmune diseases.

● Proven Clinical Success: Our CAR-T therapies have demonstrated exceptional effectiveness across numerous clinical cases, with impressive remission rates and safety profiles, reinforcing our position as a leader in immunotherapy.

● High Cost-Effectiveness: We offer a competitive edge with superior quality treatments at more accessible pricing compared to other CAR-T products on the market.

● Cutting-Edge Technology: Leveraging the latest advancements in genetic engineering, our CAR-T therapies embody the future of cancer and autoimmune disease treatment.

● Expert Clinical Support: Our experienced team of clinicians and researchers provides comprehensive care from initial consultation through therapy administration and follow-up.

CAR-T cells are now widely recognized for their efficacy in patients who have not responded to traditional treatments like chemotherapy or bone marrow transplantation. The global medical community acknowledges the groundbreaking potential of CAR-T therapy in transforming patient outcomes.

CAR-T therapy related studies and cases

1.CAR-T Therapy for Systemic Lupus Erythematosus: Remarkable Efficacy in Pediatric Case

A groundbreaking case at Erlangen University Hospital showcased the effectiveness of CAR-T cell therapy in treating a 15-year-old girl with systemic lupus erythematosus (SLE). Following a series of failed treatments, Uresa received this innovative therapy in June 2023. By three weeks post-treatment, her symptoms had significantly improved, leading to a complete recovery and restoration of kidney function. This success marks the first use of CAR-T therapy for pediatric autoimmune diseases, demonstrating its potential to achieve long-term remission and transform patient outcomes. Further research is underway to explore its applications in similar conditions.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2.CAR-T Therapy for Multiple Myeloma: Significant Remission Achieved

Bjørn Simensen, a 67-year-old patient from Norway, experienced a remarkable turnaround in his battle against multiple myeloma (IgG lambda, ISS-II) after receiving CAR-T cell therapy. Initially diagnosed in 2017, he underwent several chemotherapy regimens, but relapsed in 2021. Following ineffective treatments, he was referred to Lu Daopei Hospital in February 2022, where he was selected for CAR-T therapy. After a preconditioning regimen, his CAR-T cells were infused. By day 28, follow-up examinations revealed no abnormal plasma cells in his bone marrow, marking a significant achievement in his treatment.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3.CD7 CAR-T Therapy for Relapsed T-ALL and LBL: Promising Efficacy and Outcomes

Recent research showcases the efficacy of CD7 chimeric antigen receptor T-cell (CAR-T) therapy combined with a second allogeneic hematopoietic stem cell transplantation (HSCT) for patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). Conducted at Hebei Yanda Lu Daopei Hospital, the study involved 16 patients who achieved a remarkable 100% minimal residual disease (MRD)-negative complete remission after treatment. With a 75% complete remission rate for extramedullary lesions and one-year overall survival and leukemia-free survival rates of 58.5% and 51.4%, respectively, this innovative approach offers renewed hope for long-term remission in these aggressive cancers.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4.CAR-T Therapy for B-Cell Acute Lymphoblastic Leukemia: Unprecedented Efficacy

A recent study highlights the exceptional efficacy of chimeric antigen receptor-T cell (CAR-T) therapy in treating B-cell acute lymphoblastic leukemia (B-ALL). Conducted in collaboration with BIOOCUS and Lu Daopei Hospital, the research demonstrated that a significant number of patients achieved complete remission, positioning CAR-T therapy as a leading treatment option for this aggressive leukemia. The promising results underscore the transformative potential of CAR-T therapy in oncology, providing hope for patients and families facing B-ALL. As research progresses, CAR-T therapy is set to play a vital role in the future of cancer treatment.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

CAR-T Therapy Process

1.T-Cell Collection:

Initially, physicians collect T cells from the patient's blood using a procedure called leukapheresis. This process usually takes about 4 hours, during which a blood separator isolates the required white blood cells and returns the remaining components to the patient's body.

2.Genetic Modification and Expansion:

The collected T cells are sent to a laboratory for genetic modification. In this step, T cells are engineered to target and destroy cancer cells. This process takes approximately 2-3 weeks. During this time, the T cells are activated and expanded in the lab to ensure their effectiveness against cancer.

3.Cell Infusion:

After the engineered T cells are ready, they are reintroduced into the patient’s body through an intravenous infusion. This step allows the modified immune cells to recognize and eliminate the cancer cells effectively.

Patients may experience side effects during treatment, the most common being cytokine release syndrome (CRS), caused by the immune response during active cancer cell destruction. Although CRS can be severe, advancements in medical care have significantly reduced its risks.

The entire treatment cycle, from cell collection to infusion, typically spans 4-6 weeks, though the exact duration depends on the patient’s specific condition.

Comprehensive Support for International Patients Traveling to BIOOCUS for CAR-T Treatment

At BIOOCUS, we are dedicated to providing exceptional care and support for international patients seeking CAR-T therapy. Our comprehensive services cover every step of the journey, from pre-travel preparations to post-treatment care.

1.Pre-Travel Preparation

Before traveling to BIOOCUS, patients will undergo a detailed pre-assessment at their local medical facility. This includes a thorough review of medical history, physical examinations, and relevant tests such as blood work, imaging studies, and screenings specific to the cancer type being treated (such as leukemia, lymphoma, or other blood cancers). We ensure that all medical records, including prior treatments, test results, and diagnosis confirmations, are sent to our team for review and preparation.

2.Travel and Hospitalization

We assist with all aspects of travel, including arranging accommodation and inpatient reservations at BIOOCUS International Medical Center. Upon arrival, patients are guided through the admission process, ensuring a smooth transition into the treatment environment.

3.Treatment Process

Upon admission, patients will undergo a series of preliminary examinations, including assessments to ensure eligibility for CAR-T therapy. This will involve a review of the patient’s cancer status and overall health, as well as blood collection for T-cell extraction. The collected T-cells are then sent to our GMP-certified lab for genetic modification. This process can take approximately 2-3 weeks.

4.Cell Infusion and Post-Treatment Care

Once the modified CAR-T cells are ready, patients will return to our hospital for the infusion procedure. This is a one-time treatment where the engineered T-cells are administered intravenously. Following the infusion, patients will remain under close observation for several days to monitor for side effects, such as cytokine release syndrome, which is a potential reaction to the treatment. Our medical team provides continuous support and monitoring during this critical period.

After discharge, BIOOCUS coordinates regular follow-up visits, including laboratory tests and imaging studies, to monitor the effectiveness of the treatment and track the patient’s recovery. Patients will be closely monitored for any late effects of the therapy, and our team will remain in contact to provide ongoing guidance and support.

At BIOOCUS, we prioritize the health, safety, and comfort of our international patients. Our goal is to provide comprehensive care and ensure a supportive, seamless experience throughout the CAR-T treatment journey.

For more information about our services and how we can assist with your treatment, please contact us directly.

description2

Fill out my online form.